查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1847873

按分子類型、治療類型、患者類型、治療適應症、最終用戶和分銷管道分類的類固醇注射市場—2025-2032年全球預測

Steroid Injections Market by Molecule Type, Treatment Type, Patient Type, Therapeutic Indication, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，類固醇注射劑市場規模將達到 122.6 億美元，複合年成長率為 13.99%。

主要市場統計數據
基準年 2024 42.9億美元
預計年份：2025年 49億美元
預測年份：2032年 122.6億美元
複合年成長率 (%) 13.99%

本書權威地介紹了類固醇注射的臨床、操作和監管環境，闡述了塑造當代類固醇注射實踐和技術應用的因素。

皮質類固醇注射在現代疼痛管理和肌肉骨骼疾病治療中發揮核心作用，彌合了介入治療和保守治療之間的差距。皮質類固醇注射仍是臨床醫生治療發炎性疾病和急性發作以及針對關節、軟組織和脊椎進行標靶鎮痛的主要手段。近年來，隨著療效比較數據的累積、對標靶注射的重視以及影像引導技術的整合，臨床實踐不斷發展，以提高注射的精準性和安全性。

臨床醫生和醫院系統已調整診療流程，以平衡療效、病人安全和營運效率。同時，監管機構的監督和支付方的參與也透過強調療效、安全性以及合理使用標準，影響了診療流程的推廣應用。技術進步、對微創治療需求的不斷成長以及慢性肌肉骨骼疾病患者人口老化等因素，共同推動了類固醇注射療法的臨床應用，並持續促進製劑、給藥系統和診療方案的創新。這種應用現狀為後續分析組裝，使我們能夠將類固醇注射療法置於一個動態的臨床、商業和監管生態系統中進行探討。

精準給藥、供應鏈韌性和支付方主導的證據要求等方面的進步正在如何重塑類固醇注射的實踐和商業化

由於臨床技術的進步、供應鏈的重組以及支付方期望的轉變等因素，類固醇注射治療領域正在發生顯著變化。在臨床方面，包括超音波和透視引導在內的精準治療方法正在加速應用，從而提高標靶性並減少手術相關併發症。這一趨勢得益於強化訓練計畫以及疼痛專家、骨科醫生和介入放射科醫生之間的跨學科合作。此外，以患者為中心的治療路徑也日益受到重視，這些路徑將注射治療與康復、藥物最佳化和共用決策相結合。

在供應鏈方面，製造商和經銷商透過多元化籌資策略和投資區域製造地，應對原料短缺、物流挑戰和監管變化。同時，醫療系統加強了對治療方案價值的評估，要求提供更有力的療效比較證據和長期療效指標。技術創新不僅限於影像學，還包括標靶釋放製劑和輔助給藥系統，旨在延長症狀緩解時間並最大限度減少全身暴露。總而言之，這些轉變正在重塑類固醇注射的研發、給藥和報銷方式，促使相關人員調整商業模式和臨床通訊協定。

近期關稅調整對營運和商業的影響，以及採購、製造和分銷相關人員如何調整以維持供應連續性。

2025年實施的關稅措施為參與類固醇注射療法相關醫療產品生產、分銷和採購的相關人員帶來了更多複雜性。進口關稅和雙邊貿易措施的變化可能會影響活性藥物成分、輔料和治療用醫療設備的成本基礎，促使製造商重新審視供應商合約並探索近岸外包的機會。因此，採購團隊和對採購敏感的工廠更重視總到岸成本、前置作業時間波動和供應商多元化，以降低貿易相關價格衝擊帶來的風險。

為因應關稅壓力，價值鏈各環節已湧現多種策略性因應措施。製造商加快了對替代採購管道的評估，並調整了庫存管理方式，以平衡營運成本與供應中斷風險。經銷商和醫院系統調整了合約框架，納入了關稅轉嫁條款和更靈活的採購條件。同時，監管機構和產業協會也展開對話，以明確複雜藥品和組合器械的分類和關稅處理方式。雖然關稅不會直接改變臨床適應症或醫務人員的決策，但它促使企業在營運和商業方面做出調整，從而影響定價策略、供應連續性計劃以及產品創新速度。

透過細分市場分析了解分子偏好、手術背景、患者人口統計特徵、治療適應症、醫療環境和分銷管道，從而製定針對性策略。

對市場區隔的深入理解對於制定類固醇注射的臨床開發、商業策略和分銷計劃至關重要。從分子類型來看，此細分市場包括地塞米松、Hydrocortisone、Methylprednisolone和曲安奈德等藥物，每種藥物都有不同的療效、作用持續時間和安全性，這些因素會影響臨床選擇和製劑定位。依治療類型細分，可以區分不同的手術方式，例如關節注射、軟組織注射和脊椎注射。關節注射進一步細分為大關節和小關節注射；軟組織注射進一步細分為滑囊注射、韌帶注射和肌腱注射；脊椎注射進一步細分為硬膜外注射和鞘內注射。這些細分反映了特定手術的訓練要求、器械需求和報銷編碼的細微差別。

將患者類型細分為成人、老年人和兒童，可以顯著影響給藥策略、安全性監測和臨床結果，因為老年患者通常會合併多種疾病，這會影響治療方法的選擇和追蹤方案。治療適應症細分涵蓋腰痛、黏液囊炎、類風濕性關節炎和肌腱炎等疾病，其中腰痛再細分為下腰痛、坐骨神經痛和上腰痛。這種適應症層面的細分會影響臨床研究設計、結果指標以及臨床醫生和患者對症狀緩解的預期。最終使用者細分將門診手術中心、診所和醫院確定為主要服務場所，其中醫院進一步分為綜合醫院和專科醫院，反映了手術量、住院整合和入院資格要求的差異。分銷通路細分則著重於醫院藥局、線上藥局和零售藥局。零售藥局進一步分為連鎖藥局和獨立藥局，二者在採購行為、庫存管理能力和合約動態均有差異。整合這些細分市場，可以揭示不同的商業化路徑、針對性的證據要求以及客製化的分銷策略，製造商和服務供應商必須針對每個細分市場的臨床和營運實際情況進行設計。

亞太地區、歐洲以及中東和非洲的區域動態正在影響臨床實踐模式、監管方法和供應鏈策略。

區域動態對注射類固醇的臨床實踐模式、監管預期和商業性策略有顯著影響。在美洲，成熟的門診基礎設施、微創疼痛管理計畫的高普及率以及注重療效和合理用藥的支付方監管，共同塑造了注射類固醇的臨床應用。美洲內部的跨境貿易和採購關係也可能影響籌資策略，為區域製造中心創造機遇，從而縮短前置作業時間和降低關稅影響。

歐洲、中東和非洲是一個異質性區域，各國監管環境、報銷系統和臨床實務傳統差異顯著。這種多樣性導致了市場進入策略的多樣性，一些國家優先考慮嚴格的循證包裝，而另一些國家則採用務實的報銷模式，優先考慮門診和專科診療程序的普及。同時，亞太地區的特點是門診醫療能力的快速擴張、對臨床培訓和影像基礎設施投資的不斷成長，以及本土製造商和跨國公司並存的動態格局。該地區的相關人員必須應對當地的監管細微差別、臨床實踐模式和供應鏈結構，才能有效地部署產品和服務；區域夥伴關係和製造投資可以顯著影響產品上市速度和營運韌性。

深入了解製藥公司、醫療器材創新者和服務供應商如何整合實證醫學證據、供應鏈韌性和綜合服務，從而有效參與競爭。

類固醇注射產品和服務的競爭格局由多家企業所構成，包括成熟的製藥廠商、支援手術操作的器材供應商以及提供現場治療和培訓解決方案的專業服務機構。領先的製藥廠商正致力於透過改進配方、提高給藥品質和增強臨床安全性來打造差異化的產品組合。同時，器械廠商也不斷創新給藥系統和影像引導相容性，以提高手術精準度和工作流程效率，從而創造機會提供能夠同時滿足藥物和器械需求的捆綁式產品。

對企業而言，策略要務包括增強供應鏈韌性、投資真實世界證據的產生以及深化與關鍵終端用戶（例如門診手術中心和專科醫院）的關係。製藥公司與醫療設備供應商之間的夥伴關係，以及與醫療系統和支付方的協作，正逐漸成為加速產品應用、使商業模式與價值導向相契合的可行途徑。競爭優勢越來越依賴展現有意義的臨床結果、支援操作負責人培訓和資格認證，以及提供靈活的分銷模式（以適應醫院藥房、零售藥房和數位化採購管道日益成長的作用）的能力。能夠整合臨床證據、營運支援和供應可靠性的企業，更有能力滿足相關人員的期望並推動臨床應用。

製造商和供應商可採取的切實可行的策略重點，以加強證據產生、實現供應鏈多元化並建構一體化醫療服務解決方案。

為了在注射類固醇領域保持長期競爭力，產業領導者必須採取積極主動的策略，協調臨床證據的取得、供應鏈策略和商業性執行。首先，企業應優先投資於真實世界證據計畫和上市後研究，以明確不同適應症和給藥技術下的安全性和功能性療效。這些證據將有助於推動藥品目錄的討論、與支付方的談判以及臨床醫生的採納，同時也有助於產品的持續改進。

其次，商業和採購團隊應通力合作，實施多元化的籌資策略，並評估區域性生產方案，以降低貿易中斷和關稅波動帶來的風險。同時，應加強與醫院藥房、門診手術中心和診所網路的合作關係，透過客製化的物流解決方案和靈活的契約，提高供應的連續性。第三，企業應開發整合療法、相容的給藥裝置和訓練服務，以減少推廣應用的障礙，並改善治療效果。最後，企業領導者應儘早與支付方和監管機構合作，使循證實踐與報銷要求保持一致，並預測編碼和合理使用標準的變化。將這些建議轉化為具體的專案和跨職能計劃，有助於企業加速推廣應用，改善患者預後，並增強商業性韌性。

一項透明的混合方法研究途徑結合了臨床醫生訪談、採購洞察、監管審查和文獻綜述，以得出可靠的結論。

本分析的調查方法融合了定性和定量方法，旨在全面了解臨床實踐、供應動態和商業性促進因素。主要研究包括對常規注射類固醇的專科醫生、醫院和門診中心的採購負責人以及生產和分銷公司的高級管理人員進行結構化訪談。這些調查直接揭示了治療量、臨床對藥物分子和給藥方法的偏好，以及與庫存和採購相關的營運挑戰。

二次研究涵蓋了監管文件、臨床指南、關於皮質類固醇安全​​性和有效性的同行評審文獻，以及影響貿易和報銷的公共文件。我們也對器械註冊資料和訓練計畫採納指標的趨勢進行了全面分析，以了解影像導引手術的普及程度。透過對不同來源的數據進行三角驗證，確保結論反映的是一致的模式，而非孤立的觀察。在適用的情況下，我們的調查方法強調資料來源的透明度、分析假設的清晰度以及敏感度分析，以解釋實踐模式和供應鏈配置的差異。

總結性綜述強調了臨床價值、供應彈性以及跨職能策略是決定類固醇注射治療服務未來成功與否的關鍵因素。

總之，類固醇注射仍然是肌肉骨骼和疼痛管理實踐的重要組成部分，這得益於技術創新、針對性的臨床應用和靈活的給藥模式。相關人員面臨著由供應鏈壓力塑造的局面，包括對精準醫療服務的重視、支付方主導證據的期望以及交易相關的成本波動。一項強調強力的真實世界證據、多元化的採購管道以及整合產品和服務的策略性應對措施，對於在滿足臨床醫生和醫療機構需求的同時保持營運韌性至關重要。

展望未來，競爭優勢將取決於能否將臨床獲益轉化為可驗證的成果，確保可靠且經濟高效的供應管道，以及使商業模式與不斷變化的醫保和監管要求保持一致。臨床開發、供應鏈和商業團隊之間的跨職能協作至關重要，這能夠將洞見轉化為可擴展的項目，從而改善患者照護並維持組織績效。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 標靶關節內緩釋性類固醇製劑的應用日益增多
  • 生物相似藥注射用皮質類固醇的擴張推動了新興市場的成本競爭力
  • 整合遠端醫療平台以遠端監測和管理類固醇注射
  • 整形外科患者對微創超音波導引類固醇注射的需求日益成長
  • 對仿單標示外固醇注射行為的監管壓力促使人們制定更嚴格的合規通訊協定。
  • 開發聯合治療，用於緩解關節疼痛
  • 注射用類固醇一次性注射器和管瓶包裝的永續性舉措

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依分子類型分類的類固醇注射市場

  • 地塞米松
  • Hydrocortisone
  • Methylprednisolone
  • 曲安奈德

9. 依治療類型分類的類固醇注射市場

  • 關節注射
    • 大關節
    • 小關節
  • 軟組織注射
    • 滑囊注射
    • 韌帶注射
    • 肌腱注射
  • 脊椎注射
    • 硬脊膜外注射
    • 椎管內注射

第10章 依病患類型分類的類固醇注射市場

  • 成人
  • 老年人
  • 孩子們

第11章 以治療適應症分類的類固醇注射市場

  • 腰痛
    • 腰痛
    • 坐骨神經痛
    • 上背部疼痛
  • 黏液囊炎
  • 骨關節炎
  • 類風濕性關節炎
  • 肌腱炎

第12章 依最終用戶分類的類固醇注射市場

  • 門診手術中心
  • 診所
  • 醫院
    • 綜合醫院
    • 專科醫院

第13章 按分銷管道分類的類固醇注射市場

  • 醫院藥房
  • 網路藥房
  • 零售藥房
    • 連鎖藥局
    • 獨立藥房

第14章 各地區類固醇注射市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 類固醇注射市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國類固醇注射市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Pfizer Inc.
    • Novartis AG
    • Bayer AG
    • Johnson & Johnson
    • AbbVie Inc.
    • Merck & Co., Inc.
    • Roche Holding AG
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • Bristol-Myers Squibb Company
Product Code: MRR-4103B31E091F

The Steroid Injections Market is projected to grow by USD 12.26 billion at a CAGR of 13.99% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.29 billion
Estimated Year [2025] USD 4.90 billion
Forecast Year [2032] USD 12.26 billion
CAGR (%) 13.99%

An authoritative introduction to the clinical, operational, and regulatory landscape shaping contemporary steroid injection practice and procedural adoption

Steroid injections occupy a central role in contemporary pain management and musculoskeletal care, bridging interventional treatment and conservative therapies. Corticosteroid injections remain a mainstay for clinicians managing inflammatory conditions, acute exacerbations, and targeted pain relief across joints, soft tissues, and spinal spaces. Over recent years, clinical practice has evolved in response to accumulating comparative effectiveness data, a greater emphasis on targeted delivery, and the integration of image-guided techniques that enhance precision and safety.

Clinicians and hospital systems have adapted procedural pathways to balance efficacy, patient safety, and operational throughput. Concurrently, regulatory scrutiny and payer engagement have influenced procedural adoption by foregrounding outcomes, safety profiles, and appropriate use criteria. The combination of technological refinements, heightened demand for minimally invasive interventions, and an aging population with chronic musculoskeletal conditions has kept steroid injections in active clinical use while stimulating continued innovation in formulations, delivery systems, and procedural protocols. This introduction frames the subsequent analysis by situating steroid injections within a dynamic clinical, commercial, and regulatory ecosystem.

How advances in precision delivery, supply chain resilience, and payer-driven evidence requirements are collectively reshaping steroid injection practice and commercialization

The landscape for steroid injections is undergoing transformative shifts driven by converging clinical advances, supply chain realignments, and shifting payer expectations. Clinically, there is an accelerating adoption of precision approaches, including ultrasound and fluoroscopy guidance, which improve targeting and reduce procedure-related complications; this trend is complemented by enhanced training programs and cross-disciplinary collaboration between pain specialists, orthopedists, and interventional radiologists. Moreover, there is heightened attention to patient-centered care pathways that integrate injection therapy with rehabilitation, pharmacologic optimization, and shared decision-making.

On the supply chain front, manufacturers and distributors have responded to raw material constraints, logistics challenges, and regulatory changes by diversifying sourcing strategies and investing in regional manufacturing resilience. In parallel, health systems have intensified evaluations of procedural value, requesting stronger evidence for comparative effectiveness and longer-term outcome measures, thereby prompting manufacturers to focus on real-world evidence generation and payer engagement. Technological innovation extends beyond imaging to include targeted-release formulations and delivery adjuncts that seek to extend symptom relief while minimizing systemic exposure. Taken together, these shifts are reshaping how steroid injections are developed, delivered, and reimbursed, creating new imperatives for stakeholders to adapt commercial models and clinical protocols.

Operational and commercial repercussions of recent tariff changes and how procurement, manufacturing, and distribution stakeholders are adapting to maintain supply continuity

Tariff policies enacted in 2025 have introduced an additional layer of complexity for stakeholders involved in the manufacture, distribution, and procurement of medical products related to steroid injection therapy. Changes in import duties and bilateral trade measures have the potential to affect the cost base for active pharmaceutical ingredients, excipients, and medical devices used in procedural delivery, prompting manufacturers to reassess supplier contracts and to explore nearshoring opportunities. As a result, procurement teams and procurement-sensitive facilities have heightened their focus on total landed cost, lead-time variability, and supplier diversification to mitigate exposure to trade-related price shocks.

In response to tariff-induced pressures, several strategic responses have emerged across the value chain. Manufacturers have accelerated assessments of alternative sourcing jurisdictions and have revisited inventory policies to balance working capital considerations against the risk of supply disruptions. Distributors and hospital systems have adjusted contracting frameworks to incorporate tariff pass-through clauses and more flexible procurement terms. At the same time, regulatory authorities and industry associations have engaged in dialogue to clarify classification and duty treatments for complex pharmaceutical products and combination devices. While tariffs have not changed clinical indications or practitioner decision-making directly, they have catalyzed operational and commercial adaptations that influence pricing strategies, supply continuity planning, and the pace of product innovation.

Segment-by-segment analysis that decodes molecule preferences, procedural contexts, patient demographics, therapeutic indications, care settings, and distribution pathways for targeted strategy

A nuanced understanding of market segmentation is essential to align clinical development, commercial strategy, and distribution planning for steroid injections. When considering molecule types, the field encompasses agents such as dexamethasone, hydrocortisone, methylprednisolone, and triamcinolone, each with distinct potency profiles, duration of action, and safety considerations that influence clinical selection and formulary positioning. Treatment type segmentation delineates procedural contexts including joint injections, soft tissue injections, and spinal injections, with joint injections further differentiated by large joints and small joints, soft tissue injections subdivided into bursa injections, ligament injections, and tendon injections, and spinal injections differentiated into epidural and intrathecal procedures; these differentiations reflect procedure-specific training requirements, device needs, and reimbursement coding nuances.

Patient type segmentation-adult, geriatric, and pediatric-imposes important variations in dosing strategies, safety monitoring, and clinical outcomes, with geriatric patients often presenting comorbidities that influence therapeutic choice and follow-up protocols. Therapeutic indication segmentation covers conditions such as back pain, bursitis, osteoarthritis, rheumatoid arthritis, and tendonitis, and back pain is further analyzed across lower back pain, sciatica, and upper back pain; these indication-level distinctions inform trial design, outcome metrics, and the expected duration of symptom relief sought by clinicians and patients. End-user segmentation identifies ambulatory surgical centers, clinics, and hospitals as the primary delivery settings, with hospitals further categorized into general hospitals and specialty hospitals, reflecting differences in procedural volume, inpatient integration, and credentialing requirements. Distribution channel segmentation highlights hospital pharmacies, online pharmacies, and retail pharmacies, and retail pharmacies are further divided into chain pharmacies and independent pharmacies, indicating distinct procurement behaviors, inventory management capabilities, and contractual dynamics. Synthesizing these segmentation layers reveals differentiated commercialization pathways, targeted evidence requirements, and bespoke distribution strategies that manufacturers and service providers must design to meet the clinical and operational realities of each segment.

Regional dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence clinical practice patterns, regulatory approaches, and supply chain strategies

Regional dynamics exert a strong influence on clinical practice patterns, regulatory expectations, and commercial approaches for steroid injections. In the Americas, procedural utilization is shaped by a mature outpatient infrastructure, a high prevalence of minimally invasive pain management programs, and payer scrutiny that emphasizes outcomes and appropriate use. Cross-border trade and procurement relationships within the Americas also influence sourcing strategies and can create opportunities for regional manufacturing hubs that reduce lead times and tariff exposure.

The Europe, Middle East & Africa region presents a heterogeneous landscape where regulatory frameworks, reimbursement systems, and clinical practice traditions vary significantly across countries. This diversity encourages differentiated market access approaches, with some jurisdictions prioritizing stringent evidence packages while others adopt pragmatic reimbursement models that favor procedural adoption in ambulatory and specialized settings. Meanwhile, the Asia-Pacific region is characterized by rapid expansion of outpatient procedural capacity, growing investment in clinical training and imaging infrastructure, and a dynamic mix of local manufacturers and multinational entrants. Across regions, stakeholders must navigate local regulatory nuances, clinical practice patterns, and supply chain configurations to effectively deploy products and services, and regional partnerships or manufacturing investments can materially influence speed to market and operational resilience.

Insights into how pharmaceutical manufacturers, device innovators, and service providers are aligning evidence, supply resilience, and integrated offerings to compete effectively

The competitive landscape for steroid injection products and services is defined by a mix of established pharmaceutical manufacturers, device providers that support procedural delivery, and specialty service organizations that offer site-of-care and training solutions. Leading manufacturers prioritize portfolio differentiation through formulation improvements, quality of supply, and demonstrated clinical safety. At the same time, device makers are innovating around delivery systems and image-guidance compatibility to improve procedural precision and workflow efficiency, creating opportunities for bundled offerings that address both drug and device needs.

Strategic imperatives among companies include strengthening supply chain resilience, investing in real-world evidence generation, and cultivating deeper relationships with key end users such as ambulatory surgical centers and specialty hospitals. Partnerships between pharmaceutical firms and device providers, as well as collaborations with health systems and payer groups, have emerged as practical routes to accelerate adoption and to align commercial models with a value-based focus. Competitive differentiation increasingly hinges on the ability to demonstrate meaningful clinical outcomes, to support training and credentialing for proceduralists, and to offer flexible distribution models that account for hospital pharmacies, retail pharmacies, and the growing role of digital procurement channels. Companies that integrate clinical evidence, operational support, and supply reliability are better positioned to meet stakeholder expectations and to drive adoption across care settings.

Actionable strategic priorities for manufacturers and providers to strengthen evidence generation, diversify supply chains, and create integrated therapeutic and delivery solutions

Industry leaders must adopt a proactive posture that aligns clinical evidence generation, supply chain strategy, and commercial execution to sustain long-term competitiveness in the steroid injection space. First, organizations should prioritize investment in real-world evidence programs and post-market studies that articulate comparative safety and functional outcomes across indications and delivery techniques. Such evidence supports formulary discussions, payer negotiations, and clinician adoption while also informing continuous product improvement.

Second, commercial and procurement teams should collaborate to implement diversified sourcing strategies and to evaluate regional manufacturing options that reduce exposure to trade-related disruptions and tariff volatility. Strengthening relationships with hospital pharmacies, ambulatory surgical centers, and clinic networks through tailored logistics solutions and flexible contracting will enhance supply continuity. Third, companies should develop integrated offerings that pair therapeutics with compatible delivery devices and training services, thereby reducing barriers to adoption and improving procedural outcomes. Finally, leaders should engage early with payers and regulatory bodies to align evidence generation with reimbursement requirements and to anticipate changes in coding or appropriate use criteria. By translating these recommendations into concrete programs and cross-functional plans, organizations can accelerate adoption, enhance patient outcomes, and fortify commercial resilience.

A transparent mixed-methods research approach combining clinician interviews, procurement insights, regulatory reviews, and literature synthesis to ensure robust conclusions

The research methodology underpinning this analysis integrates qualitative and quantitative techniques to build a comprehensive understanding of clinical practice, supply dynamics, and commercial drivers. Primary research included structured interviews with clinicians across specialties that routinely perform steroid injections, procurement leaders from hospitals and outpatient centers, and senior executives at manufacturing and distribution companies. These engagements provided first-hand insights into procedure volumes, clinical preferences for molecules and delivery methods, and operational challenges related to inventory and sourcing.

Secondary research encompassed regulatory filings, clinical guidelines, peer-reviewed literature on corticosteroid safety and efficacy, and public policy documents that affect trade and reimbursement. The analysis also incorporated trend synthesis from device registries and training program adoption metrics to understand the diffusion of image-guided procedures. Data triangulation across sources ensured that conclusions reflect consistent patterns rather than isolated observations. Where applicable, the methodology emphasized transparency in data provenance, a clear articulation of analytical assumptions, and sensitivity analyses to account for variability in practice patterns and supply chain configurations.

A conclusive synthesis emphasizing clinical value, supply resilience, and cross-functional strategies as determinants of future success in steroid injection care delivery

In conclusion, steroid injections remain a vital component of musculoskeletal and pain management practice, sustained by procedural innovation, targeted clinical application, and adaptable delivery models. Stakeholders face a landscape shaped by increasing emphasis on precision delivery, payer-driven evidence expectations, and supply chain pressures that may include trade-related cost variability. Strategic responses that emphasize robust real-world evidence, diversified sourcing, and integrated product-service offerings will be central to meeting clinician and institutional needs while preserving operational resilience.

Moving forward, the ability to translate clinical efficacy into demonstrable outcomes, to secure reliable and cost-effective supply channels, and to align commercial models with evolving reimbursement and regulatory requirements will determine competitive positioning. Cross-functional collaboration across clinical development, supply chain, and commercial teams is essential to convert insights into scalable programs that improve patient care and sustain organizational performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing adoption of targeted intra-articular steroid formulations with sustained release profiles
  • 5.2. Expansion of biosimilar corticosteroid injections driving cost competition in emerging markets
  • 5.3. Integration of telehealth platforms for remote monitoring and administration of steroid injections
  • 5.4. Rising patient demand for minimally invasive ultrasound-guided steroid injection procedures in orthopedics
  • 5.5. Regulatory pressure on off-label steroid injection practices leading to stricter compliance protocols
  • 5.6. Development of combination therapies pairing corticosteroids with hyaluronic acid for joint pain relief
  • 5.7. Sustainability initiatives in single-use syringe and vial packaging for steroid injection products

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Steroid Injections Market, by Molecule Type

  • 8.1. Dexamethasone
  • 8.2. Hydrocortisone
  • 8.3. Methylprednisolone
  • 8.4. Triamcinolone

9. Steroid Injections Market, by Treatment Type

  • 9.1. Joint Injections
    • 9.1.1. Large Joints
    • 9.1.2. Small Joints
  • 9.2. Soft Tissue Injections
    • 9.2.1. Bursa Injections
    • 9.2.2. Ligament Injections
    • 9.2.3. Tendon Injections
  • 9.3. Spinal Injections
    • 9.3.1. Epidural
    • 9.3.2. Intrathecal

10. Steroid Injections Market, by Patient Type

  • 10.1. Adult
  • 10.2. Geriatric
  • 10.3. Pediatric

11. Steroid Injections Market, by Therapeutic Indication

  • 11.1. Back Pain
    • 11.1.1. Lower Back Pain
    • 11.1.2. Sciatica
    • 11.1.3. Upper Back Pain
  • 11.2. Bursitis
  • 11.3. Osteoarthritis
  • 11.4. Rheumatoid Arthritis
  • 11.5. Tendonitis

12. Steroid Injections Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Clinics
  • 12.3. Hospitals
    • 12.3.1. General Hospitals
    • 12.3.2. Specialty Hospitals

13. Steroid Injections Market, by Distribution Channel

  • 13.1. Hospital Pharmacies
  • 13.2. Online Pharmacies
  • 13.3. Retail Pharmacies
    • 13.3.1. Chain Pharmacies
    • 13.3.2. Independent Pharmacies

14. Steroid Injections Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Steroid Injections Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Steroid Injections Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Pfizer Inc.
    • 17.3.2. Novartis AG
    • 17.3.3. Bayer AG
    • 17.3.4. Johnson & Johnson
    • 17.3.5. AbbVie Inc.
    • 17.3.6. Merck & Co., Inc.
    • 17.3.7. Roche Holding AG
    • 17.3.8. Teva Pharmaceutical Industries Ltd.
    • 17.3.9. Viatris Inc.
    • 17.3.10. Bristol-Myers Squibb Company

LIST OF FIGURES

  • FIGURE 1. GLOBAL STEROID INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL STEROID INJECTIONS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL STEROID INJECTIONS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL STEROID INJECTIONS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS STEROID INJECTIONS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA STEROID INJECTIONS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL STEROID INJECTIONS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. STEROID INJECTIONS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. STEROID INJECTIONS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. STEROID INJECTIONS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL STEROID INJECTIONS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL STEROID INJECTIONS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL STEROID INJECTIONS MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL STEROID INJECTIONS MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL STEROID INJECTIONS MARKET SIZE, BY DEXAMETHASONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL STEROID INJECTIONS MARKET SIZE, BY DEXAMETHASONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL STEROID INJECTIONS MARKET SIZE, BY DEXAMETHASONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL STEROID INJECTIONS MARKET SIZE, BY DEXAMETHASONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL STEROID INJECTIONS MARKET SIZE, BY HYDROCORTISONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL STEROID INJECTIONS MARKET SIZE, BY HYDROCORTISONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL STEROID INJECTIONS MARKET SIZE, BY HYDROCORTISONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL STEROID INJECTIONS MARKET SIZE, BY HYDROCORTISONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL STEROID INJECTIONS MARKET SIZE, BY HYDROCORTISONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL STEROID INJECTIONS MARKET SIZE, BY HYDROCORTISONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL STEROID INJECTIONS MARKET SIZE, BY METHYLPREDNISOLONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL STEROID INJECTIONS MARKET SIZE, BY METHYLPREDNISOLONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL STEROID INJECTIONS MARKET SIZE, BY METHYLPREDNISOLONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL STEROID INJECTIONS MARKET SIZE, BY METHYLPREDNISOLONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL STEROID INJECTIONS MARKET SIZE, BY METHYLPREDNISOLONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL STEROID INJECTIONS MARKET SIZE, BY METHYLPREDNISOLONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TRIAMCINOLONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TRIAMCINOLONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TRIAMCINOLONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TRIAMCINOLONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TRIAMCINOLONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TRIAMCINOLONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL STEROID INJECTIONS MARKET SIZE, BY LARGE JOINTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL STEROID INJECTIONS MARKET SIZE, BY LARGE JOINTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL STEROID INJECTIONS MARKET SIZE, BY LARGE JOINTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL STEROID INJECTIONS MARKET SIZE, BY LARGE JOINTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL STEROID INJECTIONS MARKET SIZE, BY LARGE JOINTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL STEROID INJECTIONS MARKET SIZE, BY LARGE JOINTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SMALL JOINTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SMALL JOINTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SMALL JOINTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SMALL JOINTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SMALL JOINTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SMALL JOINTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL STEROID INJECTIONS MARKET SIZE, BY BURSA INJECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL STEROID INJECTIONS MARKET SIZE, BY BURSA INJECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL STEROID INJECTIONS MARKET SIZE, BY BURSA INJECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL STEROID INJECTIONS MARKET SIZE, BY BURSA INJECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL STEROID INJECTIONS MARKET SIZE, BY BURSA INJECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL STEROID INJECTIONS MARKET SIZE, BY BURSA INJECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL STEROID INJECTIONS MARKET SIZE, BY LIGAMENT INJECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL STEROID INJECTIONS MARKET SIZE, BY LIGAMENT INJECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL STEROID INJECTIONS MARKET SIZE, BY LIGAMENT INJECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL STEROID INJECTIONS MARKET SIZE, BY LIGAMENT INJECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL STEROID INJECTIONS MARKET SIZE, BY LIGAMENT INJECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL STEROID INJECTIONS MARKET SIZE, BY LIGAMENT INJECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TENDON INJECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TENDON INJECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TENDON INJECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TENDON INJECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TENDON INJECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TENDON INJECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL STEROID INJECTIONS MARKET SIZE, BY EPIDURAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL STEROID INJECTIONS MARKET SIZE, BY EPIDURAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL STEROID INJECTIONS MARKET SIZE, BY EPIDURAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL STEROID INJECTIONS MARKET SIZE, BY EPIDURAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL STEROID INJECTIONS MARKET SIZE, BY EPIDURAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL STEROID INJECTIONS MARKET SIZE, BY EPIDURAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL STEROID INJECTIONS MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL STEROID INJECTIONS MARKET SIZE, BY INTRATHECAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL STEROID INJECTIONS MARKET SIZE, BY INTRATHECAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL STEROID INJECTIONS MARKET SIZE, BY INTRATHECAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL STEROID INJECTIONS MARKET SIZE, BY INTRATHECAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL STEROID INJECTIONS MARKET SIZE, BY INTRATHECAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL STEROID INJECTIONS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL STEROID INJECTIONS MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL STEROID INJECTIONS MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL STEROID INJECTIONS MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL STEROID INJECTIONS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL STEROID INJECTIONS MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL STEROID INJECTIONS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL STEROID INJECTIONS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL STEROID INJECTIONS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL STEROID INJECTIONS MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL STEROID INJECTIONS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL STEROID INJECTIONS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL STEROID INJECTIONS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL STEROID INJECTIONS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL STEROID INJECTIONS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL STEROID INJECTIONS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL STEROID INJECTIONS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL STEROID INJECTIONS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL STEROID INJECTIONS MARKET SIZE, BY LOWER BACK PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL STEROID INJECTIONS MARKET SIZE, BY LOWER BACK PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL STEROID INJECTIONS MARKET SIZE, BY LOWER BACK PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL STEROID INJECTIONS MARKET SIZE, BY LOWER BACK PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL STEROID INJECTIONS MARKET SIZE, BY LOWER BACK PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL STEROID INJECTIONS MARKET SIZE, BY LOWER BACK PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SCIATICA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SCIATICA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SCIATICA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SCIATICA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SCIATICA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SCIATICA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL STEROID INJECTIONS MARKET SIZE, BY UPPER BACK PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL STEROID INJECTIONS MARKET SIZE, BY UPPER BACK PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL STEROID INJECTIONS MARKET SIZE, BY UPPER BACK PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL STEROID INJECTIONS MARKET SIZE, BY UPPER BACK PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL STEROID INJECTIONS MARKET SIZE, BY UPPER BACK PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL STEROID INJECTIONS MARKET SIZE, BY UPPER BACK PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL STEROID INJECTIONS MARKET SIZE, BY BURSITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL STEROID INJECTIONS MARKET SIZE, BY BURSITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL STEROID INJECTIONS MARKET SIZE, BY BURSITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL STEROID INJECTIONS MARKET SIZE, BY BURSITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL STEROID INJECTIONS MARKET SIZE, BY BURSITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL STEROID INJECTIONS MARKET SIZE, BY BURSITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL STEROID INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL STEROID INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL STEROID INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL STEROID INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL STEROID INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL STEROID INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL STEROID INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL STEROID INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL STEROID INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL STEROID INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL STEROID INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL STEROID INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TENDONITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TENDONITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TENDONITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TENDONITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TENDONITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TENDONITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL STEROID INJECTIONS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL STEROID INJECTIONS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL STEROID INJECTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL STEROID INJECTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL STEROID INJECTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL STEROID INJECTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL STEROID INJECTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL STEROID INJECTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL STEROID INJECTIONS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL STEROID INJECTIONS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL STEROID INJECTIONS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL STEROID INJECTIONS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL STEROID INJECTIONS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL STEROID INJECTIONS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL STEROID INJECTIONS MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL STEROID INJECTIONS MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL STEROID INJECTIONS MARKET SIZE, BY GENERAL HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL STEROID INJECTIONS MARKET SIZE, BY GENERAL HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL STEROID INJECTIONS MARKET SIZE, BY GENERAL HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL STEROID INJECTIONS MARKET SIZE, BY GENERAL HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SPECIALTY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SPECIALTY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SPECIALTY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SPECIALTY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SPECIALTY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SPECIALTY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL STEROID INJECTIONS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL STEROID INJECTIONS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL STEROID INJECTIONS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL STEROID INJECTIONS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL STEROID INJECTIONS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL STEROID INJECTIONS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL STEROID INJECTIONS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL STEROID INJECTIONS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL STEROID INJECTIONS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL STEROID INJECTIONS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL STEROID INJECTIONS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL STEROID INJECTIONS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL STEROID INJECTIONS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL STEROID INJECTIONS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL STEROID INJECTIONS MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL STEROID INJECTIONS MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL STEROID INJECTIONS MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL STEROID INJECTIONS MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL STEROID INJECTIONS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL STEROID INJECTIONS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL STEROID INJECTIONS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL STEROID INJECTIONS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL STEROID INJECTIONS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL STEROID INJECTIONS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL STEROID INJECTIONS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL STEROID INJECTIONS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS STEROID INJECTIONS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS STEROID INJECTIONS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS STEROID INJECTIONS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS STEROID INJECTIONS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2018-2024 (USD MILLION)
  • TABLE 300. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2025-2032 (USD MILLION)
  • TABLE 301. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2018-2024 (USD MILLION)
  • TABLE 302. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2025-2032 (USD MILLION)
  • TABLE 303. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2018-2024 (USD MILLION)
  • TABLE 304. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2025-2032 (USD MILLION)
  • TABLE 305. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
  • TABLE 308. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2032 (USD MILLION)
  • TABLE 309. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2018-2024 (USD MILLION)
  • TABLE 310. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2025-2032 (USD MILLION)
  • TABLE 311. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 312. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 313. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 314. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 315. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 316. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 317. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 318. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 319. EUROPE, MIDDLE EAST & AFRICA STEROID INJECTIONS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 320. EUROPE, MIDDLE EAST & AFRICA STEROID INJECTIONS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 321. EUROPE, MIDDLE EAST & AFRICA STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. EUROPE, MIDDLE EAST & AFRICA STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 323. EUROPE, MIDDLE EAST & AFRICA STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 324. EUROPE, MID